Company Analysis Haemonetics Corporation
1. Summary
Advantages
- The company's current efficiency (ROE=13.22%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (76.67 $) is higher than fair price (28.81 $)
- Dividends (0%) are below the sector average (1.31%).
- The stock's return over the last year (-12.82%) is lower than the sector average (-0.7555%).
- Current debt level 36.79% has increased over 5 years from 27.57%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Haemonetics Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.6% | 2.4% | -0.1% |
| 90 days | -6.3% | -4.9% | 6.5% |
| 1 year | -12.8% | -0.8% | 25% |
HAE vs Sector: Haemonetics Corporation has significantly underperformed the "Healthcare" sector by -12.06% over the past year.
HAE vs Market: Haemonetics Corporation has significantly underperformed the market by -37.79% over the past year.
Stable price: HAE is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: HAE with weekly volatility of -0.2465% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (76.67 $) is higher than the fair price (28.81 $).
Price is higher than fair: The current price (76.67 $) is 62.4% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (35.77) is lower than that of the sector as a whole (57.87).
P/E vs Market: The company's P/E (35.77) is lower than that of the market as a whole (47.68).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.38) is lower than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (4.38) is lower than that of the market as a whole (22.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.21) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (3.21) is lower than that of the market as a whole (15.21).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (18.2) is higher than that of the sector as a whole (17.62).
EV/Ebitda vs Market: The company's EV/Ebitda (18.2) is lower than that of the market as a whole (24.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 10.73% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (10.73%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-66.62%).
5.4. ROE
ROE vs Sector: The company's ROE (13.22%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (13.22%) is lower than that of the market as a whole (18.08%).
5.5. ROA
ROA vs Sector: The company's ROA (5.69%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (5.69%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (3.62%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (3.62%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.31%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (6.08%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 12.07.2024 | Lingamneni Anila EVP, Chief Technology Officer |
Sale | 90 | 7 110 | 79 |
| 11.07.2024 | Lingamneni Anila EVP, Chief Technology Officer |
Sale | 90 | 192 240 | 2 136 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
